Skip to main content

Table 1 Summary (arm-level) data from RCTs assessing biologic therapies as treatments for RA, (N - number of participants, ACR20 (%) - percent of ACR20 responders)

From: Bayesian network meta-analysis methods for combining individual participant data and aggregate data from single arm trials and randomised controlled trials

Trial

Lead author

Year

Data type

Intervention

N

ACR20 (%)

Mean RA duration (years)

1

Genovese

2008

IPD

Tocilizumab

803

60.8

9.8

1

Genovese

2008

IPD

Placebo

413

24.5

9.8

2

Smolen

2008

IPD

Tocilizumab

418

53.1

7.4

2

Smolen

2008

IPD

Placebo

204

26.5

7.8

3

Maini

1999

AD

Infliximab

340

57.4

8.3

3

Maini

1999

AD

Placebo

88

22.7

8.9

4

Weinblatt

2003

AD

Adalimumab

209

60.3

12.7

4

Weinblatt

2003

AD

Placebo

62

14.5

11.1

5

Keystone

2004

AD

Adalimumab

419

62.1

11.0

5

Keystone

2004

AD

Placebo

200

29.5

10.9

6

Chen

2008

AD

Adalimumab

35

54.3

6.2

6

Chen

2008

AD

Placebo

12

33.3

8.3

7

Kay

2008

AD

Golimumab

137

61.3

7.9

7

Kay

2008

AD

Placebo

35

37.1

5.6

8

Keystone

2009

AD

Golimumab

178

59.6

5.6

8

Keystone

2009

AD

Placebo

133

27.8

6.5

9

Kremer

2010

AD

Golimumab

257

43.6

8.8

9

Kremer

2010

AD

Placebo

129

24.8

7.4

10

Schiff

2011

AD

Infliximab

165

59.4

7.3

10

Schiff

2011

AD

Placebo

110

41.8

8.4

11

Emery

2013

AD

Golimumab

318

61.6

3.5

11

Emery

2013

AD

Placebo

160

49.4

2.9

12

Kim

2013

AD

Infliximab

71

50.7

9.8

12

Kim

2013

AD

Placebo

72

30.6

7.4

13

Tanaka

2013

AD

Golimumab

173

72.8

8.4

13

Tanaka

2013

AD

Placebo

88

33.0

8.7

14

Weinblatt

2013

AD

Golimumab

395

58.5

6.9

14

Weinblatt

2013

AD

Placebo

197

24.9

7.0